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The primary aim of the EU, with the registration of herbal medicinal 
products (HMPs), is the protection of 
the European citizens from fraudulent 
and unsafe products. In fact, the EU is 
rather rigorous on this issue and therefore 
manufacturers are obliged to deal with 
safety issues. Although a Traditional 
Herbal Medicinal Products would have 
been in circulation for centuries, it is 
possible that with time, research proves 
the presence of toxic substances within 
the product. As herbal remedies are 
derived from nature, uneven conditions 
of growth and different varieties of a 
specific plant species may contribute to 
the emergence of previously-insignificant 
plant toxins. This has been also 
experienced with herbs and plants that 
are used for culinary purposes. Therefore 
to ensure the safety of herbal medicines, 
proof can be demonstrated by employing 
a battery of in vitro and in vivo tests. 
The classical toxicity assays for herbal 
medicinal products are genotoxicity 
tests. These tests are based on the 
potential damage of plant constituents 
to DNA. The three most common forms 
of DNA damage and fixation are gene 
mutation (a change in the sequence of 
bases), chromosome mutation (structural 
alterations) and genome mutations 
(alterations in the chromosome number). 
The front line genotoxicity test is 
the AMES1 test. The test is performed 
by culturing Salmonella typhimurium 
or Escherichia coli strains that lack a 
specific amino acid, such as histidine or 
tryptophan, and challenging this culture 
with a suspected mutagen. A mammalian 
(rat) liver homogenate is added in case a 
compound requires metabolic activation 
prior to exhibiting its mutagenic effect. 
The revertent colonies are counted for 
the different mutagen concentrations 
to determine the extent of mutagenesis 
induced by the suspected compound.
The Mouse Lymphoma Assay is 
carried out on HMPs that exhibit a 
positive Ames test. Instead of the 
bacterial culture, this test utilises 
a mammalian cell model which 
distinguishes between gene and 
chromosome mutation. The result 
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obtained is compared 
with a database containing 
information on different 
chemical entities. 
The Rodent Micronucleus 
Test is appropriate to carry out 
if the DNA toxicant tested in vitro 
exhibits chromosomal alterations. In 
this test, the target organ is the bone 
marrow instead of the liver. Since the 
test involves the use of live animals, 
the rational use of animals, and whether 
the test is actually measuring what is 
expected, are taken into consideration. 
On the other hand, the use of an animal 
model may show more realistic results 
on the fate of the compounds under 
test. This establishes whether the 
compound requires hepatic activation, 
and whether it reaches the target organ.
Toxicological markers are widely 
used for herbal medicines, and these are 
classified into biological and chemical 
markers. Biological markers may be 
divided into direct and indirect toxicity 
indicators. The DNA-methyl green 
assay is an in vitro indirect method that 
determines the DNA binding capacity 
of potential toxicants. For potential 
toxicants which require metabolic 
activation, an indirect method involving 
the use of a rat model is utilised. The 
degree of toxicity can be determined 
by taking forestomach samples and 
separating the fragments by planar 
chromatography. This is typically 
performed for aristolochic2 acid. 
Chemical markers are determined by 
analytical techniques such as GCMS 
for the presence of phellandrene in 
essential oils of plants, and HPLC 
analysis for the presence of coumarins 
in plant extracts.
More recently, in silico methods 
have been developed, superseding 
most in vitro and in vivo methods. 
Although in silico models are classically 
used to predict the binding capacity 
of substrates to receptors, these are 
now used to determine qualitative 
and quantitative structure-toxicity 
relationships (STRs). A STR is a 
qualitative model that associates 
the toxic properties with a chemical 
substructure (structural alert) or a property 
limit value. This is based on chemical 
similarities. Quantitative STR relates 
the structure of the potential toxicant 
to the toxicity of structures that have 
been already studied and included in a 
database. The prediction is not merely on 
a structural resemblance but on a value-
based result with the degree of toxicity.
The technique of toxicogenomics is 
also a relative prediction tool. In this case, 
neither whole animals nor cell lines are 
used for testing. DNA microarrays reveal 
gene expression when a liver slice model 
is challenged with the potential toxicant. 
This data is compared to data of already-
established toxicants in a database.3 
Hepatotoxicity is one of the most 
important toxic effects, exhibited 
by substrates, on the human body. 
Risk assessment for hepatotoxicity is 
performed in an animal model. Doses 
are repeated at 28 days, 90 days and 
after 1 year and the effect is assessed 
as standard histopathology by light 
microscopy.4  These tests are only 
mandatory for products authorized 
as medicinal products but not for 
those placed on the market as food 
supplements.
If toxicity is established for a 
marketed herbal medicinal product, this is 
immediately withdrawn from the market. 
However, if the product is presented for 
registration, it is not allowed to reach the 
market unless it meets the required safety 
standards.  In the latter case, the product 
may be considered as a ‘minus variant’ 
which might require a slight modification. 
However, this modification should justify a 
safer profile.  
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